Vertex Pharma (VRTX) announces FDA nod gene editing therapy, Casgevy, developed with CRISPR Therapeutics (CRSP) for beta-thalassemia (TDT).
Vertex Pharma (VRTX) announces FDA nod gene editing therapy, Casgevy, developed with CRISPR Therapeutics (CRSP) for beta-thalassemia (TDT).
Comments are closed.